Rebirth of the cursed drug Thalidomide

Thalidomide was once a dreaded name in the Pharmaceutical industry. It was initially marketed in some European countries nearly 5 decades back as a sedative and after millions of pregnant women took it for morning sickness it had devastating results on the babies. The babies were born with flippers instead of limbs a condition known as phocomelia. Since then it has been under strict control.

Now reports have emerged this Sunday of its utility in a rare hereditary blood disorder called hereditary haemorrhagic telangiectasia, or HHT, which causes frequent, hard-to-treat nosebleeds. The occurrence of this disease is really rare with only one in 10,000 getting it.

Research on Thalidomide has for many years been concentrated on its utility in other diseases like Amyotrophic lateral sclerosis, Behcet's syndrome, Brain, Breast and Colorectal cancer, Congestive heart failure, Crohn's disease, HIV infections, Hodgkin's disease, Kaposi's sarcoma, Leukaemia, Myelofibrosis, Myeloid leukaemia and Non-Hodgkin's lymphoma.

Since then a drug with similar chemical structure called Revlimid was made by US ‘pharma’ company Celgene and approved for use in multiple myeloma.

Researchers in France have shown that genetically engineered mice who had HHT showed beneficial results when given Thalidomide. There was a reduced risk of bleeding and blood vessels were better stabilized with Thalidomide. According to the scientists from the National Institute of Health and Medical Research (INSERM) as they report in the journal Nature Medicine, Thalidomide acts here by improving a protein called PDGF-B.

Franck Lebrin, one of the lead researchers of this study said "Biopsies of the nasal surface tissue from patients with HHT showed that similar mechanisms may explain the effects of thalidomide treatment in humans."

Dr. Ananya Mandal

Written by

Dr. Ananya Mandal

Dr. Ananya Mandal is a doctor by profession, lecturer by vocation and a medical writer by passion. She specialized in Clinical Pharmacology after her bachelor's (MBBS). For her, health communication is not just writing complicated reviews for professionals but making medical knowledge understandable and available to the general public as well.


Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Mandal, Ananya. (2018, August 23). Rebirth of the cursed drug Thalidomide. News-Medical. Retrieved on June 17, 2024 from

  • MLA

    Mandal, Ananya. "Rebirth of the cursed drug Thalidomide". News-Medical. 17 June 2024. <>.

  • Chicago

    Mandal, Ananya. "Rebirth of the cursed drug Thalidomide". News-Medical. (accessed June 17, 2024).

  • Harvard

    Mandal, Ananya. 2018. Rebirth of the cursed drug Thalidomide. News-Medical, viewed 17 June 2024,


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Research finds sugar tax may lower childhood asthma hospital admission rates by 20.9%